Chromocell Therapeutics Corp financial data

Symbol
CHRO on NYSE
Location
685 Us Highway One, North Brunswick, NJ
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 56.2 %
Debt-to-equity -228 %
Return On Equity 582 %
Return On Assets -454 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.03M shares
Common Stock, Shares, Outstanding 5.82M shares
Common Stock, Value, Issued 583 USD
Weighted Average Number of Shares Outstanding, Basic 5.79M shares +488%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 3.19M USD +744%
General and Administrative Expense 4.22M USD +75.5%
Operating Income (Loss) -9.63M USD -58.6%
Nonoperating Income (Expense) -443K USD
Net Income (Loss) Attributable to Parent -10.1M USD -19.2%
Earnings Per Share, Basic 7.89 USD/shares +79.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.8M USD
Assets, Current 2.14M USD
Assets 2.14M USD
Accrued Liabilities, Current 308K USD
Liabilities, Current 3.57M USD
Liabilities 3.57M USD
Retained Earnings (Accumulated Deficit) -19.5M USD
Stockholders' Equity Attributable to Parent -1.43M USD +75.8%
Liabilities and Equity 2.14M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.99M USD -1049%
Net Cash Provided by (Used in) Financing Activities 5.67M USD +3295%
Common Stock, Shares Authorized 200M shares
Common Stock, Shares, Issued 5.82M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.25M USD +5407%
Additional Paid in Capital 18.1M USD